Group 1 - The company held its 16th meeting of the 5th Supervisory Board on May 27, 2025, which was conducted both in-person and via communication methods [1] - The meeting was chaired by Mr. Zhang Jie, and all three supervisors attended, confirming the legality and validity of the meeting procedures [1] - The Supervisory Board unanimously approved the proposal to renew the appointment of the financial auditing and internal control auditing institutions for the year 2025 [1] Group 2 - The Supervisory Board expressed confidence in Da Xin Accounting Firm (Special General Partnership) due to its extensive experience in auditing listed companies, ensuring it meets the company's auditing needs [1] - The appointment of the financial and internal control auditing institutions complies with relevant laws and regulations, and will not affect the quality of the company's financial statements [1] - The proposal will be submitted to the company's shareholders' meeting for further approval [2]

Core Viewpoint - The company intends to reappoint Da Xin Accounting Firm as its financial and internal control auditor for the year 2025, pending approval from the shareholders' meeting [2][8]. Group 1: Appointment of Auditor - The board of directors proposes to reappoint Da Xin Accounting Firm for the 2025 annual financial audit and internal control audit, with the term starting from the resolution of the 2024 annual shareholders' meeting until the 2025 annual shareholders' meeting [2][8]. - Da Xin Accounting Firm was established in 1985 and has transitioned to a special general partnership since March 2012, with its headquarters located in Beijing and 33 branches across the country [2][3]. - The firm has extensive experience in securities services, being one of the earliest accounting firms in China to engage in such services, and has nearly 30 years of experience in the securities business [2][3]. Group 2: Auditor's Qualifications - As of December 31, 2024, Da Xin has a total of 3,957 employees, including 1,031 certified public accountants, with over 500 having signed securities service audit reports [3]. - The firm has not faced any criminal penalties in the past three years, but has received 6 administrative penalties and 14 administrative regulatory measures [3]. - Da Xin's audit revenue was 1.38 billion yuan, with securities business revenue of 450 million yuan, and it audited 204 listed companies in 2023 [3]. Group 3: Audit Team Composition - The project partner and signing CPA, He Zheng, has been engaged in auditing listed companies since 2003 and has signed reports for several companies [4]. - The signing CPA, Jiang Kun, has been providing audit services since 2010 and has worked with the company since 2022 [5]. - The quality control reviewer, Li Hong, has experience in quality review and has executed audits for multiple listed companies [6]. Group 4: Audit Fee Structure - The internal control audit fee is set at 350,000 yuan, with the board proposing to authorize management to negotiate specific remuneration based on the audit workload and market conditions [6][8]. - The pricing principles for audit fees consider the responsibilities and professional expertise required, as well as the experience and rates of the participating staff [6]. Group 5: Approval Process - The audit committee has reviewed Da Xin Accounting Firm and confirmed its qualifications and experience in auditing listed companies, recommending its reappointment [7]. - Independent directors have also expressed their approval, stating that Da Xin meets the necessary qualifications and can fulfill the company's auditing needs [7]. - The board and supervisory committee have both approved the proposal to reappoint Da Xin, which will be submitted for shareholder approval [8].

Core Viewpoint - The company has implemented a "Quality Improvement, Efficiency Enhancement, and Return to Shareholders" action plan to enhance investor confidence and promote sustainable development, with a focus on core business and innovation in orthopedic products [1][2][5]. Group 1: Business Development and Innovation - The company has been dedicated to the research, production, and sales of orthopedic consumables since its establishment in 1998, continuously expanding its product line and market share both domestically and internationally [1]. - In 2024, the company invested approximately 133 million yuan in R&D, accounting for 16.52% of its revenue, with plans to further enhance its orthopedic product line and diversify its offerings in 2025 [2]. - Several products have become the first or unique in the domestic market, enhancing the company's core competitiveness and industry recognition [3]. Group 2: Product Line Expansion - The company is developing high-value-added products in response to market and clinical needs, including shoulder and elbow joint products, and has received registration approvals for various small joint replacement products [3][4]. - The company is also advancing its dental product solutions and PRP preparation systems, with plans for further innovation in robotic products for joint surgeries [4]. - The company aims to create a diversified revenue matrix through the expansion of its product lines and the optimization of existing business operations [4]. Group 3: Corporate Governance and Management - The company emphasizes the importance of a sound governance structure and effective internal control systems, aligning its development strategy with sustainable business practices [5]. - It has revised its governance policies in accordance with regulatory requirements and is committed to fulfilling its social responsibilities while balancing the interests of all stakeholders [5]. Group 4: Shareholder Returns and Market Confidence - The company has implemented a profit distribution policy that considers industry characteristics and operational stages, with cash dividends of approximately 120 million yuan in 2022 and 138 million yuan in 2023 [6][7]. - The company has actively engaged in H-share buybacks to boost investor confidence and stabilize its stock price, having repurchased 868,145 shares as of June 2024 [7][8]. Group 5: Investor Relations and Information Disclosure - The company prioritizes investor relations management and adheres to legal and regulatory requirements for information disclosure, ensuring transparency and accuracy in communicating its financial and operational status [8][9]. - It aims to enhance the quality of information disclosure and maintain a stable and high-quality investor base to support long-term market confidence [9]. Group 6: Continuous Evaluation and Improvement - The company will continuously assess the implementation of its action plan and focus on core business and cost efficiency to fulfill its responsibilities as a listed company and reward investor trust [9].

Group 1 - The company announced the resignation of two senior executives: Vice President Zhai Zhiyong and Chief Financial Officer Li Yumei, both resigning for personal reasons but will continue to work within the company [1][2] - Zhai Zhiyong holds 4,960 shares in the company, while Li Yumei does not hold any shares [1] - The board expressed gratitude for the contributions made by Zhai Zhiyong and Li Yumei during their tenure [2] Group 2 - The company appointed Lu Hongyue as the new Chief Financial Officer, effective from the date of the board's approval [2] - Lu Hongyue, born in April 1993, graduated from North China University of Science and Technology with a degree in accounting and has held various financial roles since 2015 [4] - Lu Hongyue does not hold any shares in the company and has no related party relationships with the company's directors, supervisors, or major shareholders [4]

独立董事：徐泓、翁杰、黄德盛 日期：2025 年 5 月 27 日 我们作为北京市春立正达医疗器械股份有限公司（以下简称"公司"）的独 立董事，根据相关法律法规及规范性文件的规定，基于独立判断的立场，就公司 第五届董事会第二十四次会议审议的相关事项发表独立意见如下： 一、《关于续聘公司 2025 年度境内外财务审计机构及内控审计机构的议案》 我们认为：经审查，大信会计师事务所（特殊普通合伙）具备相关业务的执 业资格，具有多年为上市公司进行审计的经验和能力，能够满足公司财务审计和 内控审计的工作需要。我们认为本次聘请的财务审计机构及内控审计机构符合相 关法律法规和审议程序，不会影响公司正常会计报表的审计质量，不会损害全体 股东和投资者的合法权益，同意续聘大信会计师事务所（特殊普通合伙）为公司 2025 年境内外财务审计机构及内控审计机构。同意将该议案提交公司 2024 年度 股东大会审议。 北京市春立正达医疗器械股份有限公司 独立董事关于第五届董事会第二十四次会议 相关事项的独立意见 ...

北京市春立正达医疗器械股份有限公司 独立董事关于第五届董事会第二十四次会议 相关事项的事前认可意见 公司拟聘请的大信会计师事务所（特殊普通合伙）具有多年为上市公司提供 审计服务的经验与能力，经认真审查相关资料，大信会计师事务所具备相关业务 的执业资格，能够满足公司境内外财务审计和内控审计的工作需要。其在为公司 提供 2024 年度的审计服务工作中恪尽职守，遵循独立、客观、公正的职业准则， 出具的各项报告客观、真实地反映了公司情况。我们同意《关于续聘公司 2025 年度境内外财务审计机构及内控审计机构的议案》提交第五届董事会第二十四次 会议审议。 我们作为北京市春立正达医疗器械股份有限公司（以下简称"公司"）的独 立董事，根据相关法律法规及规范性文件的规定，基于独立判断的立场，对公司 拟在第五届董事会第二十四次会议审议的相关议案等文件资料进行了事前审核， 现就相关事项发表事前认可意见如下： 独立董事：徐泓、翁杰、黄德盛 日期：2025 年 5 月 27 日 一、《关于续聘公司 2025 年度境内外财务审计机构及内控审计机构的议案》 的事前认可意见 ...

北京市春立正达医疗器械股份有限公司 关于高级管理人员辞任及聘任财务总监的公告 证券代码：688236 证券简称：春立医疗 公告编号：2025-021 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 特此公告。 北京市春立正达医疗器械股份有限公司 北京市春立正达医疗器械股份有限公司（以下简称"公司"）于 2025 年 5 月 27 日召开第五届董事会第二十四次会议，审议通过了《关于高级管理人员辞任及 聘任财务总监的议案》。具体情况如下： 一、高级管理人员辞任情况 董事会于近日收到公司副总经理翟志永先生和财务总监李玉梅女士递交的书 面辞职申请，翟志永先生因个人原因申请辞去公司副总经理的职务，辞任后，翟 志永先生将在公司继续任职；李玉梅女士因个人原因申请辞去公司财务总监的职 务，辞任后，李玉梅女士将在公司继续任职。 截至本公告披露日，翟志永先生持有公司股份 4,960 股，李玉梅女士未持有公 司股份。辞任后，翟志永先生、李玉梅女士会继续严格遵守《中华人民共和国公 司法》（以下简称"《公司法》"）《上海证券交易所上市公司自律监管指 ...

北京市春立正达医疗器械股份公司 2025 年度"提质增效重回报"专项行动方案 北京市春立正达医疗器械股份公司（以下简称"公司"或"春立医疗"）为践行以 "投资者为本"的上市公司发展理念，维护公司全体股东利益，增强投资者信心，促进 公司健康可持续发展，于 2024 年 3 月 29 日在上海证券交易所披露了《2024 年度"提质 增效重回报"专项行动方案》，并于 2024 年 8 月 31 日披露了《2024 年度提质增效重回 报专项行动方案的半年度评估报告》。2024 年度，公司根据上述行动方案内容积极开展 和落实相关工作，在保障投资者权益、树立良好资本市场形象等方面取得了一定成效。 2025 年，公司将结合自身发展战略和经营情况，制定 2025 年度"提质增效重回报" 专项行动方案，努力通过规范的公司治理，持续创造价值，提升经营水平，重视投资回 报，切实履行上市公司的责任和义务，为构建良好的投资者关系贡献自身的力量。现将 2025 年度"提质增效重回报"专项行动方案报告如下： 一、 聚焦主业发展，持续创新研发，扩充产品线 公司自 1998 年成立以来，一直致力于骨科耗材的研发、生产及销售。凭借创新的 研发团 ...

证券代码：688236 证券简称：春立医疗 公告编号：2025-019 北京市春立正达医疗器械股份有限公司 关于续聘 2025 年度境内外财务报表审计和内部控制审计 一、拟续聘会计师事务所的情况说明 为保持审计工作的连续性和稳定性，经董事会审计委员会提议，并经全体独 立董事事前认可，公司拟续聘大信会计师事务所（特殊普通合伙）为公司 2025 年度境内外财务审计机构及内控审计机构，聘期自 2024 年年度股东大会决议之 日起至 2025 年年度股东大会召开之日止，董事会提请股东大会授权管理层根据 2025 年公司审计工作量和市场价格情况等与大信协商确定具体报酬。 二、拟聘任会计师事务所的基本情况 会计师事务所的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 拟聘任的会计师事务所名称：大信会计师事务所（特殊普通合伙）（以下 简称："大信会计师事务所""大信"）。 本事项尚需提交公司股东大会审议。 （一）机构信息 1.机构信息 大信会计师事务所成立于 1985 年，2012 年 3 月转制为特殊普通合伙制事 ...

北京市春立正达医疗器械股份有限公司 股东大会会议资料 H 股代码：01858 A 股代码：688236 证券简称：春立医疗 北京市春立正达医疗器械股份有限公司 2024 年年度股东大会、 2025 年第一次 A 股类别股东大会及 2025 年第一次 H 股类别股东大会 会议资料 二〇二五年六月 1 | 会议须知 3 | | --- | | 会议议程 5 | | 会议议案 7 | | 议案一：《关于公司 2024 年年度报告及其摘要的议案》 7 | | 议案二：《关于公司 2024 年度利润分配方案的议案》 8 | | 议案三：《关于〈2024 年度独立董事述职报告〉的议案》 9 | | 议案四：《关于〈2024 年度董事会工作报告〉的议案》 10 | | 议案五：《关于公司 2024 年度财务决算报告的议案》 11 | | 议案六：《关于公司 2025 年度董事薪酬的议案》 12 | | 议案七：《关于授予董事会回购 H 股的一般性授权的议案》 13 | | 议案八：《关于公司 2025 年度监事薪酬的议案》 14 | | 议案九：《关于〈2024 年度监事会工作报告〉的议案》 15 | | 议案十：《关于公 ...